AdoShell® Islets is an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy and AdoGel® Sema a technology enabling the sustained release of semaglutide.
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced oral presentations at EASD 2024, unveiling the latest results obtained on AdoShell® Islets, an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy, and on AdoGel® Sema, a technology enabling the sustained release of semaglutide.
The 60th annual congress of the EASD (European Association for the Study of Diabetes) will be held from September 9 to 13, in Madrid, Spain.